ICD-10-PCS FY2022 (April) code changes

Historical release · ICD-10-PCS FY2022 (April) · Effective April 1, 2022 – September 30, 2022 ICD-10-PCS FY2027 is the release in force (effective October 1, 2026).

Part of FY2022 coding changes

Every recorded ICD-10-PCS code addition, deletion, description revision, billable-status change and tabular-instruction change for FY2022 (April), effective April 1, 2022.

These changes are based on recorded release data. MedCoder does not generate coding changes with AI.

Release: ICD-10-PCS FY2022 (April)
Effective: April 1, 2022
Code set period: 2022-04-01 through 2022-09-30

FY2022 (April) at a glance

9Added9 of them valid for submission

Explore the complete recorded change list →

Compare a code

Enter any ICD-10-PCS code to see what this release does to it: added, deleted, description revised, billable status changed, new child codes, or no change at all. The answer is a lookup against the recorded changes below — nothing is generated.

The full recorded change list

Every recorded change, grouped by what kind of change it is. Each entry shows the code's own description first; tabular instructions and relationship text are labeled separately beneath it.

Added to the code set (9)

XW013V7 — Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
XW013W7 — Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
XW023V7 — Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7
XW023W7 — Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7
XW023X7 — Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
XW023Y7 — Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
XW0DXR7 — Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7
XW0G7R7 — Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7
XW0H7R7 — Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7

Sources

Official source data

Publisher: Centers for Medicare & Medicaid Services (CMS) and the National Center for Health Statistics (CDC/NCHS)
Release: ICD-10-PCS FY2022 (April)
Source file: errata-january-12-2022.zip
File checksum (SHA-256): 42f947eeb2adda37dec0781324a602d7af19cfdbdabc304c391af50752a37264
Rebuilt snapshot: The snapshot compared here is CMS's December 2021 code file plus the 2 codes in CMS's January 12, 2022 errata. It matches the valid codes in the order file CMS shipped with that errata.
Data type: Public domain code descriptions and tabular instructions. No licensed content.

MedCoder-derived analysis

Change detection: Every addition, deletion, description revision, billable-status change and tabular-instruction change on this page is computed by diffing the two code-description files above, line by line.
Editorial analysis: The grouping of changes into themes, the successor determinations and the coder-impact notes are written by MedCoder against those files. They are not CMS statements.
Independence: MedCoder is an independent coding reference built on public federal data. It is not affiliated with, endorsed by or certified by CMS, and it is not an official CMS coding tool.

Continue

All releases in the Change Ledger